REPROS THERAPEUTICS INC's ticker is RPRX and the CUSIP is 76028H209.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $9,000 | +125.0% | 13,551 | 0.0% | 0.00% | – |
Q3 2017 | $4,000 | -33.3% | 13,551 | 0.0% | 0.00% | – |
Q2 2017 | $6,000 | -62.5% | 13,551 | 0.0% | 0.00% | – |
Q1 2017 | $16,000 | -15.8% | 13,551 | 0.0% | 0.00% | – |
Q4 2016 | $19,000 | -34.5% | 13,551 | -2.2% | 0.00% | – |
Q3 2016 | $29,000 | +38.1% | 13,851 | 0.0% | 0.00% | – |
Q2 2016 | $21,000 | +61.5% | 13,851 | 0.0% | 0.00% | – |
Q1 2016 | $13,000 | -18.8% | 13,851 | 0.0% | 0.00% | – |
Q4 2015 | $16,000 | -84.5% | 13,851 | 0.0% | 0.00% | – |
Q3 2015 | $103,000 | -36.0% | 13,851 | -38.6% | 0.00% | – |
Q2 2015 | $161,000 | -94.8% | 22,551 | -93.8% | 0.00% | – |
Q1 2015 | $3,110,000 | -13.3% | 362,040 | +0.7% | 0.00% | – |
Q4 2014 | $3,588,000 | -66.8% | 359,459 | -67.1% | 0.00% | -100.0% |
Q3 2014 | $10,818,000 | -32.1% | 1,092,615 | +18.6% | 0.00% | -50.0% |
Q2 2014 | $15,937,000 | -17.3% | 921,128 | -15.2% | 0.00% | 0.0% |
Q1 2014 | $19,279,000 | -44.7% | 1,086,636 | -44.0% | 0.00% | 0.0% |
Q4 2013 | $34,854,000 | +73.9% | 1,940,063 | +159.5% | 0.00% | 0.0% |
Q3 2013 | $20,039,000 | +282.9% | 747,748 | +163.6% | 0.00% | +100.0% |
Q2 2013 | $5,234,000 | – | 283,652 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 1,001,000 | $970,000 | 0.21% |
Allegis Investment Advisors, LLC | 341,669 | $331,000 | 0.19% |
GENERAL AMERICAN INVESTORS CO INC | 396,123 | $384,000 | 0.04% |
Alambic Investment Management, L.P. | 114,591 | $111,000 | 0.04% |
Gruss Capital Management LP | 600,000 | $582,000 | 0.02% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 102,086 | $99,000 | 0.01% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 323,429 | $314,000 | 0.01% |
GSA CAPITAL PARTNERS LLP | 27,931 | $27,000 | 0.00% |
BENJAMIN F. EDWARDS & COMPANY, INC. | 2,700 | $3,000 | 0.00% |
Airain ltd | 13,690 | $13,000 | 0.00% |